Kailera Therapeutics (NASDAQ:KLRA) Now Covered by Analysts at Evercore

Evercore began coverage on shares of Kailera Therapeutics (NASDAQ:KLRA) in a research report released on Tuesday morning, Marketbeat.com reports. The firm issued an outperform rating on the stock.

Other equities research analysts have also recently issued research reports about the company. William Blair initiated coverage on Kailera Therapeutics in a research note on Tuesday. They set an “outperform” rating on the stock. TD Cowen started coverage on Kailera Therapeutics in a report on Tuesday. They set a “buy” rating and a $57.00 target price on the stock. Wall Street Zen raised Kailera Therapeutics to a “hold” rating in a report on Saturday, April 25th. Finally, Jefferies Financial Group started coverage on Kailera Therapeutics in a report on Tuesday. They set a “buy” rating and a $48.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $42.75.

Kailera Therapeutics Price Performance

Shares of Kailera Therapeutics stock opened at $22.30 on Tuesday. Kailera Therapeutics has a 12-month low of $20.86 and a 12-month high of $28.23.

Insider Buying and Selling

In other news, Director Adam Koppel acquired 1,562,500 shares of the firm’s stock in a transaction on Monday, April 20th. The shares were purchased at an average cost of $16.00 per share, with a total value of $25,000,000.00. Following the acquisition, the director directly owned 22,583,268 shares in the company, valued at $361,332,288. This represents a 7.43% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Andrew T. Kaplan acquired 8,398,438 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the acquisition, the director owned 26,255,581 shares in the company, valued at approximately $420,089,296. This represents a 47.03% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 10,460,938 shares of company stock valued at $167,375,008.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.